Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03617458 · ClinicalTrials.gov registry record · Phase 2
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT03617458 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 73 participants.
The verdict
NCT03617458, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health Organization (WHO) functional class in humans with pulmonary artery hypertension (PAH).
Interventions
- DRUG Placebo
- DRUG Metformin
- DEVICE mHealth Intervention
- DEVICE Usual Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2025-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03617458
The ClinicalTrials.gov registry entry for NCT03617458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03617458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03617458 about?
NCT03617458 is a clinical study titled "Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension". The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health Organization (WHO) functional class in humans with pulmonary artery hyperten...
What is the current status of trial NCT03617458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2018-08-23. Estimated completion is 2025-08-19.
What interventions are being tested in trial NCT03617458?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), mHealth Intervention (DEVICE), Usual Care (DEVICE).
Who is sponsoring clinical trial NCT03617458?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.